NO305124B1 - Derivater av amidanaloger av visse methano-broede kinoliziner - Google Patents

Derivater av amidanaloger av visse methano-broede kinoliziner Download PDF

Info

Publication number
NO305124B1
NO305124B1 NO922270A NO922270A NO305124B1 NO 305124 B1 NO305124 B1 NO 305124B1 NO 922270 A NO922270 A NO 922270A NO 922270 A NO922270 A NO 922270A NO 305124 B1 NO305124 B1 NO 305124B1
Authority
NO
Norway
Prior art keywords
methano
trans
quinolizin
octahydro
compounds
Prior art date
Application number
NO922270A
Other languages
English (en)
Norwegian (no)
Other versions
NO922270D0 (no
NO922270L (no
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO922270D0 publication Critical patent/NO922270D0/no
Publication of NO922270L publication Critical patent/NO922270L/no
Publication of NO305124B1 publication Critical patent/NO305124B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO922270A 1991-06-11 1992-06-10 Derivater av amidanaloger av visse methano-broede kinoliziner NO305124B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91401550A EP0517984A1 (fr) 1991-06-11 1991-06-11 Derivés d'analogues d'amide de quinolizines à pont méthano

Publications (3)

Publication Number Publication Date
NO922270D0 NO922270D0 (no) 1992-06-10
NO922270L NO922270L (no) 1992-12-14
NO305124B1 true NO305124B1 (no) 1999-04-06

Family

ID=8208580

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922270A NO305124B1 (no) 1991-06-11 1992-06-10 Derivater av amidanaloger av visse methano-broede kinoliziner

Country Status (16)

Country Link
EP (2) EP0517984A1 (fr)
JP (1) JP3377227B2 (fr)
KR (1) KR100234926B1 (fr)
AT (1) ATE214392T1 (fr)
AU (1) AU649836B2 (fr)
CA (1) CA2070573C (fr)
DE (1) DE69232473T2 (fr)
DK (1) DK0518767T3 (fr)
ES (1) ES2173863T3 (fr)
FI (1) FI112866B (fr)
HU (1) HU212735B (fr)
IE (1) IE921874A1 (fr)
IL (1) IL102132A (fr)
NO (1) NO305124B1 (fr)
NZ (1) NZ243031A (fr)
PT (1) PT518767E (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
EP0628043A1 (fr) * 1992-02-24 1994-12-14 Merrell Pharmaceuticals Inc. Derive de 2,6-methano-2h-quinolizine utilise comme antagoniste de recepteur de 5-ht 3?
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
DK1030667T3 (da) * 1997-11-14 2005-06-20 Akzo Nobel Nv Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
US7160898B2 (en) 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
CA2321900C (fr) 1998-02-27 2011-07-19 The Board Of Trustees Of The University Of Illinois Agents presentant une activite de type serotonine pour le traitement des apnees du sommeil
US7666867B2 (en) 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
CA2590802A1 (fr) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Compositions pharmaceutiques destinees a des troubles du sommeil
WO2007081890A2 (fr) 2006-01-05 2007-07-19 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Production du dolasetron
CN101774971B (zh) * 2010-02-10 2011-07-27 山东众诚药业股份有限公司 高纯度1-甲基吲唑-3-羧酸的生产方法
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2024052684A1 (fr) 2022-09-09 2024-03-14 MyricX Pharma Limited Conjugué anticorps-médicament comprenant un inhibiteur de nmt et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB219363A (en) * 1923-03-24 1924-07-24 Abraham Preston Improvements in or in connection with bed couches
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
EP0330788A1 (fr) * 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture des médicaments pour le traitement de l'arythmie cardiaque
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
JP3377227B2 (ja) 2003-02-17
FI922695A0 (fi) 1992-06-10
EP0518767B1 (fr) 2002-03-13
AU649836B2 (en) 1994-06-02
HU9201939D0 (en) 1992-08-28
KR930000518A (ko) 1993-01-15
FI112866B (fi) 2004-01-30
HUT61549A (en) 1993-01-28
DE69232473T2 (de) 2002-11-21
NO922270D0 (no) 1992-06-10
PT518767E (pt) 2002-09-30
ES2173863T3 (es) 2002-11-01
KR100234926B1 (ko) 1999-12-15
CA2070573A1 (fr) 1992-12-12
IL102132A0 (en) 1993-01-14
AU1803792A (en) 1992-12-24
EP0517984A1 (fr) 1992-12-16
HU212735B (en) 1996-10-28
IL102132A (en) 1996-10-31
ATE214392T1 (de) 2002-03-15
DE69232473D1 (de) 2002-04-18
JPH05202044A (ja) 1993-08-10
FI922695L (fi) 1992-12-12
EP0518767A2 (fr) 1992-12-16
NZ243031A (en) 1994-02-25
NO922270L (no) 1992-12-14
DK0518767T3 (da) 2002-07-01
CA2070573C (fr) 2003-04-15
EP0518767A3 (en) 1993-05-05
IE921874A1 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
US5011846A (en) Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
KR100258052B1 (ko) 5ht2c-수용체 길항제로서의 피리미딘 유도체 및 이를 포함하는 약물
Anzini et al. Novel, potent, and selective 5-HT3 receptor antagonists based on the arylpiperazine skeleton: synthesis, structure, biological activity, and comparative molecular field analysis studies
AU649836B2 (en) Derivatives of amide analogs of certain methano bridged quinolizines
JPH054983A (ja) イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する５−ｈｔ３ レセプター拮抗剤
KR900002245B1 (ko) 테트라하이드로-2-헤테로사이클로알킬-피리도[4,3-b]인돌 및 그의 제조방법
US5955470A (en) Derivatives of amide analogs of certain methano bridged quinolizines
IE83573B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
JP2001512727A (ja) ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
US5563147A (en) Serotonerbic tetrahydropyridoindoles
EP0586560A1 (fr) Nouveaux composes de benzopyrido piperidylidene, compositions, procedes de preparation et d'utilisation
NO172437B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidindionforbindelser
JPH08502273A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド
US5262537A (en) Derivatives of 4,5,6,7-tetrahydroimidazo-[4,5-c]pyridinyl-6-carboxylic acid
US20060183905A1 (en) Derivatives of 4-(thio-or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist
RU2314305C2 (ru) Производные 4-(тио- или селеноксантен-9-илиден)-пиперидина или акридина, фармацевтическая композиция на их основе и применение
US5096900A (en) (4-piperidyl)methyl-2,3-dihydro-1h-isoindole and -2,3,4,5-tetrahydro-1h-benzazepine derivatives, their preparation and their application in therapy
BRPI0619422A2 (pt) derivados de cromona úteis como antagonistas de receptores vr1
DK175643B1 (da) Anvendelse af quinolizin- og quinolizinon-derivater ved fremstilling af lægemidler
JPH09512025A (ja) ５ｈｔ▲下２ｃ▼および５ｈｔ▲下２ｂ▼アンタゴニストとしての三環式誘導体
WO2000049017A1 (fr) Dioxydes de 1-((indoly azacycloalkyl) alkyl)-2,1, 3-benzothiadiazole 2,2 faisant montre d'une activite de recepteur 5-ht2a
US6057340A (en) Oxazole derivatives as serotonin-1A receptor agonists
JPH0733744A (ja) インダゾール誘導体およびその塩
JP2005239578A (ja) ５−ｈｔ１ａ作動作用と５−ｈｔ３拮抗作用を併有する薬剤
US5681836A (en) Methanesulfonate salts of antipsychotic benzofuran derivatives

Legal Events

Date Code Title Description
MK1K Patent expired